IL-17 Inhibitors By Novartis, Lilly Don’t Show Suicide Signal, Firms Say
This article was originally published in The Pink Sheet Daily
Amgen’s decision to withdraw from its collaboration with AstraZeneca to develop IL-17 inhibitor brodalumab for psoriasis due to concerns over suicide ideation has focused attention on the safety of other IL-17 agents.
You may also be interested in...
AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.
Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.
Policymakers should instead focus on increasing efficiencies in drug development, distribution and reimbursement, National Academies report says, while also seeking broad policies like HHS direct negotiation for drug prices in Medicare.